Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921086 | 0.82 | MAOA (0.42) | MAOAMAOBTDP1HTR4GPR3 | |
| SCHEMBL516091 | 0.78 | TDP1 (0.59) | MAOAMAOBTDP1ACHEGPR3 | |
| SCHEMBL17083434 | 0.74 | MAOA (0.46) | MAOAMAOBTDP1ACHEGPR3 | |
| SCHEMBL29314509 | 0.74 | ADORA3 (0.43) | MAOAMAOBTDP1ACHEKDM4E | |
| SCHEMBL1919858 | 0.73 | MAOA (0.48) | MAOAMAOBTDP1ACHEGPR3 | |
| SCHEMBL822532 | 0.72 | GPR3 (0.46) | MAOATDP1ACHEHTR4GPR3 | |
| SCHEMBL822669 | 0.72 | GPR3 (0.59) | MAOAACHEHTR4GPR3KCNH2 | |
| SCHEMBL17083433 | 0.70 | LMNA (0.46) | MAOAMAOBTDP1GPR3KDM4E | |
| SCHEMBL856788 | 0.70 | TDP1 (0.54) | MAOAMAOBTDP1ACHEGPR3 | |
| SCHEMBL29461212 | 0.70 | TDP1 (0.54) | MAOAMAOBTDP1ACHEGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102099358-B | Compound with serotoninergic activity, process for preparing same and pharmaceutical composition comprising same | ACRAF | 2014-01-22 | — | — | CN | disclosed |
| EP-2326645-B9 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | ACRAF (IT) | 2013-04-17 | — | — | EP | disclosed |
| EP-2326645-B1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | ACRAF (IT) | 2012-11-07 | — | — | EP | disclosed |
| US-20110160201-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | AZIENDE CHIMI. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-06-30 | — | — | US | disclosed |
| CN-102099358-A | Compound with serotoninergic activity, process for preparing same and pharmaceutical composition comprising same | ACRAF | 2011-06-15 | — | — | CN | disclosed |
| EP-2326645-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010012611-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160201-A1 | COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT | TPH1, TPH2, HTR1A | MAOA 27/4885MAOB 25/4885TDP1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.